Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 8;2(2):otaa045. doi: 10.1093/crocol/otaa045

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Perception of MC hazards compared to existing pharmaceutical classes used for IBD management. Over half the cohort rated MC as less hazardous than immunomodulators and corticosteroids. N = 88 responses (n = 87 for corticosteroids). Percentage of total responses in each category (agree, neutral, and disagree) shown.